On February 2, 2021, The Lancet published preliminary findings regarding data collected from about 20,000 participants. The study itself split the participants into fourths, giving one fourth the placebo and the other third fourths received two shots of the actual vaccine. After an interim analysis of the Sputnik V vaccine’s third phase results, CNN states that the vaccine is proven to be 91.6% effective against symptomatic Covid-19. The study only analyzed the vaccine against symptomatic and the authors stated that more research is needed to review the effects against asymptomatic cases. 

According to CNN, the Sputnik V vaccine is a “two-dose adenoviral vector vaccine using two different adenoviruses for each dose, with doses administered 21 days apart.” After receiving both doses, “Over 98% of volunteers in the vaccine group developed humoral immune response and 100% cellular immune response,” stated the official Sputnik Vaccine website. Not only is the vaccine effective, but it is also stated to have “showed excellent safety profile. Most adverse events (94%) were mild and included flu-like syndromes, injection site reactions, headache and asthenia.”

Now that the vaccine has been proven to be effective, shipments have been sent and the vaccine has been registered in over fifteen countries, says Sputnik Vaccine. On Wednesday, February 3, Palestine received 100,000 doses of the Sputnik V vaccine, according to The Jerusalem Post, and according to Aljazeera, Iran also received a shipment.